The emerging role of P-glycoprotein inhibitors in drug delivery: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 4, 2011, Pages 561-576

  Akhtar, Naseem ^a,b   Ahad, Abdul ^a   Khar, Roop Kishan ^a   Jaggi, Manu ^b   Aqil, Mohammed ^a   Iqbal, Zeenat ^a   Ahmad, Farhan Jalees ^a   Talegaonkar, Sushama ^a  

^a HAMDARD UNIVERSITY   (India)

^b Fresenius Kabi Oncology   (India)

Author keywords

Bioavailability enhancement; MDR reversal; P glycoprotein; P glycoprotein inhibitor; patent survey

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CLOFAZIMINE; CYCLOSPORIN; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; ELETRIPTAN; ESSENTIAL OIL; GELUCIRE; GLYCOPROTEIN P INHIBITOR; GUM BENZOIN; IRINOTECAN; LABRASOL; MACROGOL 10000; MACROGOL 400; MIGLYOL; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; NALTREXONE; PACLITAXEL; PIPERAZINE DERIVATIVE; POLYSORBATE 80; PROTEIN FARNESYLTRANSFERASE INHIBITOR; QUINOLINE DERIVATIVE; TOCOFERSOLAN; TPGS 1000; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; XANTHAN;

BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; MIGRAINE; NONHUMAN; REVIEW;

ANIMALS; CALCIUM CHANNEL BLOCKERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEIN; PATENTS AS TOPIC; POLYMERS; SURFACE-ACTIVE AGENTS;

EID: 79952903674     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.561784     Document Type: Review

References (100)

1. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett 2006;21:998-1009 Accounts the timeline of significant discoveries related to MDR. (Pubitemid 43185280)
2. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as p-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12(1):46-78
3. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters-present status and challenges. Expert Opin Drug Metab Toxicol 2008;4(2):205-23 Review summarizes recent advances in the development of less toxic modulators, including small molecules and natural products. (Pubitemid 351308418)
4. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 2007;55:1-15 (Pubitemid 46108588)
5. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 2007;113:429-41 (Pubitemid 46149055)
6. Colabufo NA, Berardi F, Cantore M, et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: Pharmaceutical, biological, and diagnostic potentials. J Med Chem 2010;53:1883-97
7. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83
8. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. Pglycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 2003;48:347-59 Excellent review explores the techniques used for screening P-gp inhibitors and the scope of these inhibitors in optimizing peroral drug absorption. (Pubitemid 36945333)
9. McKeegan KS, Borges-Walmsley MI, Walmsley AR. Structural understanding of efflux-mediated drug resistance: Potential routes to efflux inhibition. Curr Opin Pharmacol 2004;4:479-86 (Pubitemid 40533008)
10. Boesch D, Gaveriaux C, Jachez B, et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991;51:4226-33
11. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10(2):159-65 The review compares and contrasts the properties of the new third generation of P-gp inhibitors with those of earlier generation. (Pubitemid 36437822)
12. Coley HM. Overcoming multidrug resistance in cancer: Clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010;596:341-58
13. Ponte-Sucre A. Availability and applications of ATP-binding cassette (ABC) transporter blockers. Appl Microbiol Biotechnol 2007;76:279-86 (Pubitemid 47101682)
14. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters-present status and challenges. Expert Opin Drug Metab Toxicol 2008;4(2):205-23 Review summarizes recent advances in the development of less toxic modulators, including small molecules and natural products. (Pubitemid 351308418)
15. Bansal T, Akhtar N, Jaggi M, et al. Novel formulation approaches for optimising delivery of anticancer drugs based on p-glycoprotein modulation. Drug Discov Today 2009;14:21-2 Excellent review explores the possibility of using pharmaceutical excipients as P-gp inhibitors and various co-development strategies for the formulation of cytotoxic drugs.
16. Lee BD, Li Z, French KJ, et al. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem 2004;47(6):1413-22 (Pubitemid 38327468)
17. Xenova Ltd. Anthranilic acid derivatives as multi drug resistance modulators. US6218393B1; 2001
18. Degenhardt CR, Eickhoff DJ. Substituted heterocyclic compounds for treating multidrug resistance. US7135483; 2006
19. Perez-Tomas R. Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859-76
20. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel17402 cell line. Cancer Lett 1999;135:97-105
21. Pfizer, Inc. Compositions having improved bioavailability. US20020165120; 2002
22. Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37:300-5 The paper reports that vincristine-verapamil-PLGA nanoparticles: The most potential approach to achieve the highest MDR reversal efficacy.
23. Bansal T, Mishra G, Jaggi M, et al. Effect of p-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of Irinotecan in rats. Eur J Pharm Sci 2009;36:580-90 Investigation reports the effect of verapamil on the function of intestinal P-gp on Caco-2 cells.
24. Candussio L, Decorti G, Crivellato E, et al. Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci 2002;71:3109-19 (Pubitemid 35284357)
25. Slater L, Sweet P, Wetzel M, et al. Comparison of cyclosporine A, verapamil, PSC-833, and cremophor EL, as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 1995;19(8):543-48
26. Saito T, Zhang ZJ, Tokuriki M, et al. Cyclosporine A inhibits the extrusion pump function of p-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin. Brain Res 2001;901:265-70 (Pubitemid 32718831)
27. Teva North America. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents. US200710060635A1; 2007
28. Zomanex LLC. Methods and formulations for converting intravenous and injectable drugs into oral dosage forms. US20090088393; 2009
29. Hayward NJ, Gefter ML. Methods for enhancing the bioavailability of a drug. US200510288222A1; 2005
30. Arimori K, Kuroki N, Hidaka M, et al. Effect of p-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003;20(6):910-17 (Pubitemid 36628439)
31. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006;580:2903-09 (Pubitemid 43729172)
32. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991;27:1639-42
33. Lo Y, Liu F, Cherng J. Effect of PSC 833 liposomes and intralipid on the transport of epirubicin in Caco-2 cells and rat intestines. J Control Release 2001;76:1-10 This paper reports drug-intralipid formulation: Antagonize the effect of free valspodar (PSC833) on epirubicin pharmacokinetics and decrease the exacerbated toxicities. (Pubitemid 32786880)
34. Novartis. Combination comprising a P-gp inhibitor and an anti-epileptic drug. US20070142266; 2007
35. Van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646-54 (Pubitemid 41510736)
36. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319-29
37. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003;46:4805-17 (Pubitemid 37352018)
38. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-602 (Pubitemid 23304385)
39. De Bruin M, Miyake K, Litman T, et al. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-26 (Pubitemid 29492880)
40. Glaxo Group Ltd. Methods and compositions for increasing penetration of HIV protease inhibitors. WO1999064001; 1999
41. Van Tellingen. Methods and means for the treatment of cancer. US20090170880; 2009
42. Kawamura K, Yamasaki T, Yui J, et al. In vivo evaluation of p-glycoprotein and breast cancer resistance protein modulation in the brain using [11C] gefitinib. Nucl Med Biol 2009;36:239-46
43. Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) mediated active efflux. J Pharmacol Exp Ther 2010;334(1):147-55
44. Sugimoto H, Hirabayashi H, Kimura Y, et al. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metab Dispos 2011;39(1):8-14 The paper reports the clinically used P-gp inhibitors do not cause drug-drug interaction at the human BBB.
45. Pajeva IK, Wiese M. Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J 2009;11:435-44
46. Fox E, Bates SE. Tariquidar (XR9576) a P-glycoprotein drug efflux pump inhibitor. Exp Rev Anticancer Ther 2007;7(4):447-59 (Pubitemid 46681800)
47. Kuntner C, Bankstahl JP, Bankstahl M, et al. Dose-response assessment of tariquidar and elacridar and regional quantification of p-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C] verapamil PET. Eur J Nucl Med Mol Imaging 2010;37(5):942-53
48. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant advanced breast cancer. Cancer 2005;104:682-91 (Pubitemid 41114904)
49. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79
50. Sato W, Fukazawa N, Suzuki T, et al. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 1991;51:2420-4
51. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999;290:854-62 (Pubitemid 29344586)
52. Kember EM, Cleypool C, Boogerd W, et al. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration in mice. Cancer Chemother Pharmacol 2004;53(2)173-8 (Pubitemid 38186997)
53. Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991-02
54. Rege BD, Kaob JPY, Pollia JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237-46
55. Collnot EM, Baldes C, Wempe MF, et al. Influence of vitamin E TPGS poly (ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 2006;111:35-40 (Pubitemid 43289992)
56. Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005;25:445-53 (Pubitemid 40853872)
57. Wempe MF, Lehr CM, Collnot EM, et al. Methods and pharmaceutical formulations for increasing bioavailability. US20070060610; 2007
58. Zhang L, Zhang YD, Strong JM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008;38:709-24
59. Hyatt JA, Zima GC, Edgar KJ, et al. Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations. US200610165769A1; 2006
60. Shen Q, Lin Y, Handa T. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006;313:49-56
61. Aventis Pharmaceuticals, Inc. Method of enhancing bioavailability of fexofenadine and its derivatives. US6451815; 2002
62. Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of p-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119-31 Investigates the excipients/surfactants that can modify the pharmacokinetics of orally administered drugs that are P-gp substrates. (Pubitemid 38670443)
63. Lin Y, Shen Q, Katsumi H, et al. Effects of labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats. Biol Pharm Bull 2007;7:1301-7 (Pubitemid 47037658)
64. Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds. US20050191343; 2005
65. Sri International. Orally-absorbed solid dose formulation for vancomycin. US20090111736; 2009
66. Aventis Pharma. Galenic applications of self-emulsifying mixtures of lipidic excipients. US20080193519; 2008
67. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 2008;25:500-11 Excellent review explores the polymeric efflux pumps inhibitors and their use in cancer therapy as well as in drug delivery.
68. Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release 2006;111:41-6 (Pubitemid 43289993)
69. Thio Matrix Forschungs. Use of compounds containing thiol groups as efflux pump inhibitors. US20080200563; 2008
70. Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnurch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release 2010;147(1):62-9
71. Iqbal J, Sarti F, Perera G, et al. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 2011;32(1):170-5
72. Pfizer, Inc. Method of increasing the bioavailability and tissue penetration of azithromycin. US20040091527; 2004
73. Foger F, Malaivijitnond S, Wannaprasert T, et al. Effect of a thiolated polymer on oral paclitaxel absorption and tumor growth in rats. J Drug Target 2008;16(2):149-55 (Pubitemid 351266551)
74. Sachs-Barrable K, Thamboo A, Lee DS, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci 2007;10:319-31 Investigates the influence of Peceol® and Gelucire® 44/14 on the transport of Rho123 and the protein expression of P-gp in a well-established cell culture model of intestinal absorption. (Pubitemid 350055592)
75. D-Pharm Ltd. Use of branched chain fatty acids and derivatives thereof for inhibition of p-glycoprotein. US6605638B1; 2003
76. Lienau P, Backensfeld T, Reichel A, Jung T. Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally. US200410223983A1; 2004
77. Hanmi Pharm CoLtd. P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same. US20070072900A1; 2007
78. Eli Lilly and Co. Drug resistance and multidrug resistance modulators. US6180633; 2001
79. Smith CD. Compounds for enhancing chemotherapy. US6693112B2; 2004
80. Merrell Pharmaceuticals, Inc. Diarylalkyl piperidines useful as multi-drug resistant tumor agents. US5648365; 1997
81. Merrell Pharmaceuticals, Inc. Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives. US5670521; 1997
82. Pfizer, Inc. Compounds enhancing antitumor activity of other cytotoxic agents. US6130217; 2000
83. Berardi F, Colabufo NA, Perrone R, et al. 1-Phenylalcoxy-2-beta- phenylethyl derivatives as p-glycoprotein (P-gp) inhibitors useful in drug resistance events. US20090093493; 2009
84. Schering Corp. Methods for treating multidrug resistance. US6703400B2; 2004
85. Medlen CE, Anderson R, O'Sullivan JF. MDR resistance treatment and novel pharmaceutically active riminophenazines. US5763443; 1998
86. Badalian AM. Aryl-indane compounds. US20020128231A1; 2002
87. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005;17:86-95 (Pubitemid 40463763)
88. Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007;2:601-7 Excellent review on the utility of terpenes as penetration enhancers and also presents the mechanism of penetration of terpenes.
89. Ahad A, Aqil M, Kohli K, et al. Chemical penetration enhancers: A patent review. Expert Opin Ther Pat 2009;19(7):969-88 Excellent review on the utility of different class of penetration enhancers.
90. Av Max, Inc. Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds. US6121234; 2000
91. Av Max, Inc. Use of benzoin gum to inhibit p-glycoprotein-mediated resistance of pharmaceutical compounds. US5916566; 1999
92. Eurand International. Compositions with enhanced oral bioavailability. WO2001052896; 2001
93. Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier. US7034036B2; 2006
94. Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier. US200710054932A1; 2007
95. Chung H, Jeong SY, Kwon IC, et al. P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient. US200610141033A1; 2006
96. Salphati L, Benet LZ. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998;56:308-13 (Pubitemid 28246381)
97. Benet L, Wu CY. Screening method for the identification of bioenhancers through the inhibition of p-glycoprotein transport in the gut of a mammal. US5567592; 1996
98. Benet LZ, Wu CY. Method for increasing bioavailability of oral pharmaceutical compositions. US6028054; 2000
99. Pfizer, Inc. Method of increasing the bioavailability and tissue penetration of azithromycin. US200410091527A1; 2004
100. Mitra AK, Majumdar S, Jain R, Nashed Y. Peptidyl prodrugs that resist p-glycoprotein mediated drug efflux. US200710142302A1; 2007